Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy

NCT03629782 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03629782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03629782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 26, 2018
Completion date
July 31, 2020
Enrollment
1,032 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma